Go to content
UR Home

Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II

Dietz, A. ; Wichmann, G. ; Kuhnt, T. ; Pfreundner, L. ; Hagen, R. ; Scheich, M. ; Kölbl, O. ; Hautmann, M. G. ; Strutz, J. ; Schreiber, F. ; Bockmühl, U. ; Schilling, V. ; Feyer, P. ; de Wit, M. ; Maschmeyer, G. ; Jungehülsing, M. ; Schroeder, U. ; Wollenberg, B. ; Sittel, C. ; Münter, M. ; Lenarz, T. ; Klussmann, J. P. ; Guntinas-Lichius, O. ; Rudack, C. ; Eich, H. T. ; Foerg, T. ; Preyer, S. ; Westhofen, M. ; Welkoborsky, H. J. ; Esser, D. ; Thurnher, D. ; Remmert, S. ; Sudhoff, H. ; Görner, M. ; Bünzel, J. ; Budach, V. ; Held, S. ; Knödler, M. ; Lordick, F. ; Wiegand, S. ; Vogel, K. ; Boehm, A. ; Flentje, M. ; Keilholz, U.



Abstract

Background: The German multicenter randomized phase II larynx organ preservation (LOP) trial DeLOS-II was carried out to prove the hypothesis that cetuximab (E) added to induction chemotherapy (IC) and radiotherapy improves laryngectomy-free survival (LFS; survival with preserved larynx) in locally advanced laryngeal/hypopharyngeal cancer (LHSCC). Patients and methods: Treatment-naive patients ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons